News

The progress report on the safety and clinical efficacy of GAIA-102 against pediatric solid malignant tumors will be presented at the 66th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology

At the European Society for Medical Oncology 2024, the interim report of the clinical trial for peritoneal dissemination (gastric/pancreatic cancer) will be presented

Notice of Adoption of AMED Grant for Development of Production Methods Aimed at Practical Application of Regenerative Medical Products

At IMMUNOLOGY 2024, research results about GAIA-102 were presented

DLT evaluation of the monotherapy cohort for GAIA-102 in the clinical trial for pediatric patients with relapsed/refractory solid malignancies has been completed

Research results related to the cultivation technology of GAIA-102 received the Excellent Presentation Award at the 23rd Congress of the Japanese Society for Regenerative Medicine

The clinical trial “GAIA-102 Intraperitoneal Administration in Patients with Advanced Gastrointestinal Cancer of Microsatellite Stable with Malignant Ascites” has been adopted by AMED as part of ’Research Project for Practical Applications of Regenerative Medicine’.

At the 96th Annual Meeting of Japanese Gastric Cancer Association, an interim report on the Phase Ⅰ/Ⅱ trial of intraperitoneal infusion of GAIA-102 for gastric/pancreatic cancer will be presented.

At the 9th Annual Innate Killer Summit (IKS2024), Clinical Activity of GAIA-102 Against Refractory/Relapsed Pediatric Solid Tumors will be presented.

At the 38th Annual Meeting of Society of Immunotherapy of Cancer (SITC2023), Interim Report of Phase I Clinical Trial of Pseudoprogression and subsequent shrinkage of refractory/relapsed pediatric solid tumors induced by GAIA-102